Relatlimab + Nivolumab for Advanced Melanoma
(RELATIVITY-047 Trial)

Recruiting in Palo Alto (17 mi)

+259 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2 & 3

Waitlist Available

Sponsor: Bristol-Myers Squibb

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial is testing if using two medications together (relatlimab and nivolumab) is better than using just one (nivolumab) for treating a type of skin cancer that can't be removed by surgery or has spread. The drugs help the immune system to better recognize and attack cancer cells.

Eligibility Criteria

This trial is for individuals with advanced melanoma that can't be removed by surgery or has spread, and who haven't had previous systemic cancer treatments. They must have a confirmed diagnosis of Stage III (unresectable) or Stage IV melanoma and provide tumor tissue for analysis. People with active brain metastases, uveal melanoma, or autoimmune diseases cannot participate.

Inclusion Criteria

My melanoma is at an advanced stage and cannot be surgically removed.

I have not received systemic anticancer therapy for my advanced melanoma.

I can provide a tissue sample from my cancer that cannot be surgically removed.

Exclusion Criteria

I do not have cancer that has spread to my brain or its coverings.

I do not have eye melanoma.

I do not have any known autoimmune diseases.

Treatment Details

Interventions

Nivolumab (Checkpoint Inhibitor)
Relatlimab (Checkpoint Inhibitor)

Trial OverviewThe study is testing the effectiveness of combining two drugs: Relatlimab and Nivolumab versus using Nivolumab alone in treating advanced melanoma. The goal is to see if the combination works better than just one drug on its own.

Participant Groups

2Treatment groups

Experimental Treatment

Group I: Arm B: NivolumabExperimental Treatment1 Intervention

Monotherapy

Group II: Arm A: Relatlimab + NivolumabExperimental Treatment2 Interventions

Combination

Nivolumab is already approved in United States, European Union, Canada, Switzerland for the following indications:

🇺🇸 Approved in United States as Opdivo for: